Mitochondrial disorders as a mechanism for the development of obese Sarcopenia

Obese sarcopenia is a severe and prevalent disease in an aging society. Compared to sarcopenia alone, the development and advanced stage of obesity sarcopenia is faster and more severe. Diagnosis of the cause of adipocyte accumulation is also more complicated; however, no effective pharmacological t...

Full description

Saved in:
Bibliographic Details
Published in:Diabetology and metabolic syndrome 2023-11, Vol.15 (1), p.1-224, Article 224
Main Authors: Liao, Tingfeng, Xiong, Lijiao, Wang, Xiaohao, Yang, Shu, Liang, Zhen
Format: Article
Language:English
Subjects:
Adipocytes
Atrophy
Autophagy
Body fat
Developmental stages
Diabetes
Diet
Disease
Disease susceptibility
Drug therapy
Exercise
Inflammation
Insulin resistance
Lipids
Metabolic disorders
Mitochondria
Mitochondrial DNA
Musculoskeletal system
Myasthenia gravis
Neuromuscular junctions
Obesity
Oxidation
Oxidative stress
Physical fitness
Proteins
Review
Sarcopenia
Type 2 diabetes
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c523t-23fa5e20766913fbbc15cf8f43c2843fcfcfc256b7a3651bce417a78ba3435b13
container_end_page 224
container_issue 1
container_start_page 1
container_title Diabetology and metabolic syndrome
container_volume 15
creator Liao, Tingfeng
Xiong, Lijiao
Wang, Xiaohao
Yang, Shu
Liang, Zhen
description Obese sarcopenia is a severe and prevalent disease in an aging society. Compared to sarcopenia alone, the development and advanced stage of obesity sarcopenia is faster and more severe. Diagnosis of the cause of adipocyte accumulation is also more complicated; however, no effective pharmacological treatment is available. Chronic inflammation is one of the causes of sarcopenia, and obese patients, who are more likely to develop chronic inflammation, may simultaneously suffer from obesity and sarcopenia. Mitochondrial metabolic disorders have been more easily observed in the tissue cells of patients with obesity and sarcopenia. Mitochondrial metabolic disorders include abnormal mtDNA release, mitochondrial autophagy, and dynamic mitochondrial disorders. Therefore, this review will reveal the mechanism of development of obesity myasthenia gravis from the perspective of mitochondria and discuss the currently existing small-molecule drugs.
doi_str_mv 10.1186/s13098-023-01192-w
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_cd563a25562a47e185b7f5b9f818bfc6</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A771651301</galeid><doaj_id>oai_doaj_org_article_cd563a25562a47e185b7f5b9f818bfc6</doaj_id><sourcerecordid>A771651301</sourcerecordid><originalsourceid>FETCH-LOGICAL-c523t-23fa5e20766913fbbc15cf8f43c2843fcfcfc256b7a3651bce417a78ba3435b13</originalsourceid><addsrcrecordid>eNptkl1rFTEQhhdRbK3-Aa8WBPFmaz42H3slpfhRqHqhXodJdnI2h93NMdlt8d-b01O0R2QCCZN3nmFepqpeUnJOqZZvM-Wk0w1hvCGUdqy5fVSdUiV0I7pOPn7wPqme5bwlRCqh2qfVCVcdk5rK0-rL57BEN8S5TwHGug85ph5TrqGcekI3wBzyVPuY6mXAuscbHONuwnmpo6-jxYz1N0gu7nAO8Lx64mHM-OL-Pqt-fHj__fJTc_3149XlxXXjBONLw7gHgYwoKTvKvbWOCue1b7ljuuXe7YMJaRVwKah12FIFSlvgLReW8rPq6sDtI2zNLoUJ0i8TIZi7REwbA2kJbkTjeiE5MCEkg1Yh1cIqL2znNdXWO1lY7w6s3Won7F0ZLcF4BD3-mcNgNvHGUCKZVEQVwpt7Qoo_V8yLmUJ2OI4wY1yzYVpLSUpnXaSv_pFu45rm4lVRdYQo0Un2V7WBMkGYfSyN3R5qLpSixRJO9iac_0dVoscpuDijDyV_VPD6QcGAMC5DjuO6hDjnYyE7CF2KOSf0f9ygxOx3zxx2z5TdM3e7Z275b9KFyTk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2890075962</pqid></control><display><type>article</type><title>Mitochondrial disorders as a mechanism for the development of obese Sarcopenia</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Liao, Tingfeng ; Xiong, Lijiao ; Wang, Xiaohao ; Yang, Shu ; Liang, Zhen</creator><creatorcontrib>Liao, Tingfeng ; Xiong, Lijiao ; Wang, Xiaohao ; Yang, Shu ; Liang, Zhen</creatorcontrib><description>Obese sarcopenia is a severe and prevalent disease in an aging society. Compared to sarcopenia alone, the development and advanced stage of obesity sarcopenia is faster and more severe. Diagnosis of the cause of adipocyte accumulation is also more complicated; however, no effective pharmacological treatment is available. Chronic inflammation is one of the causes of sarcopenia, and obese patients, who are more likely to develop chronic inflammation, may simultaneously suffer from obesity and sarcopenia. Mitochondrial metabolic disorders have been more easily observed in the tissue cells of patients with obesity and sarcopenia. Mitochondrial metabolic disorders include abnormal mtDNA release, mitochondrial autophagy, and dynamic mitochondrial disorders. Therefore, this review will reveal the mechanism of development of obesity myasthenia gravis from the perspective of mitochondria and discuss the currently existing small-molecule drugs.</description><identifier>ISSN: 1758-5996</identifier><identifier>EISSN: 1758-5996</identifier><identifier>DOI: 10.1186/s13098-023-01192-w</identifier><identifier>PMID: 37926816</identifier><language>eng</language><publisher>London: BioMed Central Ltd</publisher><subject>Adipocytes ; Atrophy ; Autophagy ; Body fat ; Developmental stages ; Diabetes ; Diet ; Disease ; Disease susceptibility ; Drug therapy ; Exercise ; Inflammation ; Insulin resistance ; Lipids ; Metabolic disorders ; Mitochondria ; Mitochondrial DNA ; Musculoskeletal system ; Myasthenia gravis ; Neuromuscular junctions ; Obesity ; Oxidation ; Oxidative stress ; Physical fitness ; Proteins ; Review ; Sarcopenia ; Type 2 diabetes</subject><ispartof>Diabetology and metabolic syndrome, 2023-11, Vol.15 (1), p.1-224, Article 224</ispartof><rights>COPYRIGHT 2023 BioMed Central Ltd.</rights><rights>2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c523t-23fa5e20766913fbbc15cf8f43c2843fcfcfc256b7a3651bce417a78ba3435b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626707/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2890075962?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768</link.rule.ids></links><search><creatorcontrib>Liao, Tingfeng</creatorcontrib><creatorcontrib>Xiong, Lijiao</creatorcontrib><creatorcontrib>Wang, Xiaohao</creatorcontrib><creatorcontrib>Yang, Shu</creatorcontrib><creatorcontrib>Liang, Zhen</creatorcontrib><title>Mitochondrial disorders as a mechanism for the development of obese Sarcopenia</title><title>Diabetology and metabolic syndrome</title><description>Obese sarcopenia is a severe and prevalent disease in an aging society. Compared to sarcopenia alone, the development and advanced stage of obesity sarcopenia is faster and more severe. Diagnosis of the cause of adipocyte accumulation is also more complicated; however, no effective pharmacological treatment is available. Chronic inflammation is one of the causes of sarcopenia, and obese patients, who are more likely to develop chronic inflammation, may simultaneously suffer from obesity and sarcopenia. Mitochondrial metabolic disorders have been more easily observed in the tissue cells of patients with obesity and sarcopenia. Mitochondrial metabolic disorders include abnormal mtDNA release, mitochondrial autophagy, and dynamic mitochondrial disorders. Therefore, this review will reveal the mechanism of development of obesity myasthenia gravis from the perspective of mitochondria and discuss the currently existing small-molecule drugs.</description><subject>Adipocytes</subject><subject>Atrophy</subject><subject>Autophagy</subject><subject>Body fat</subject><subject>Developmental stages</subject><subject>Diabetes</subject><subject>Diet</subject><subject>Disease</subject><subject>Disease susceptibility</subject><subject>Drug therapy</subject><subject>Exercise</subject><subject>Inflammation</subject><subject>Insulin resistance</subject><subject>Lipids</subject><subject>Metabolic disorders</subject><subject>Mitochondria</subject><subject>Mitochondrial DNA</subject><subject>Musculoskeletal system</subject><subject>Myasthenia gravis</subject><subject>Neuromuscular junctions</subject><subject>Obesity</subject><subject>Oxidation</subject><subject>Oxidative stress</subject><subject>Physical fitness</subject><subject>Proteins</subject><subject>Review</subject><subject>Sarcopenia</subject><subject>Type 2 diabetes</subject><issn>1758-5996</issn><issn>1758-5996</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkl1rFTEQhhdRbK3-Aa8WBPFmaz42H3slpfhRqHqhXodJdnI2h93NMdlt8d-b01O0R2QCCZN3nmFepqpeUnJOqZZvM-Wk0w1hvCGUdqy5fVSdUiV0I7pOPn7wPqme5bwlRCqh2qfVCVcdk5rK0-rL57BEN8S5TwHGug85ph5TrqGcekI3wBzyVPuY6mXAuscbHONuwnmpo6-jxYz1N0gu7nAO8Lx64mHM-OL-Pqt-fHj__fJTc_3149XlxXXjBONLw7gHgYwoKTvKvbWOCue1b7ljuuXe7YMJaRVwKah12FIFSlvgLReW8rPq6sDtI2zNLoUJ0i8TIZi7REwbA2kJbkTjeiE5MCEkg1Yh1cIqL2znNdXWO1lY7w6s3Won7F0ZLcF4BD3-mcNgNvHGUCKZVEQVwpt7Qoo_V8yLmUJ2OI4wY1yzYVpLSUpnXaSv_pFu45rm4lVRdYQo0Un2V7WBMkGYfSyN3R5qLpSixRJO9iac_0dVoscpuDijDyV_VPD6QcGAMC5DjuO6hDjnYyE7CF2KOSf0f9ygxOx3zxx2z5TdM3e7Z275b9KFyTk</recordid><startdate>20231106</startdate><enddate>20231106</enddate><creator>Liao, Tingfeng</creator><creator>Xiong, Lijiao</creator><creator>Wang, Xiaohao</creator><creator>Yang, Shu</creator><creator>Liang, Zhen</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20231106</creationdate><title>Mitochondrial disorders as a mechanism for the development of obese Sarcopenia</title><author>Liao, Tingfeng ; Xiong, Lijiao ; Wang, Xiaohao ; Yang, Shu ; Liang, Zhen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c523t-23fa5e20766913fbbc15cf8f43c2843fcfcfc256b7a3651bce417a78ba3435b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adipocytes</topic><topic>Atrophy</topic><topic>Autophagy</topic><topic>Body fat</topic><topic>Developmental stages</topic><topic>Diabetes</topic><topic>Diet</topic><topic>Disease</topic><topic>Disease susceptibility</topic><topic>Drug therapy</topic><topic>Exercise</topic><topic>Inflammation</topic><topic>Insulin resistance</topic><topic>Lipids</topic><topic>Metabolic disorders</topic><topic>Mitochondria</topic><topic>Mitochondrial DNA</topic><topic>Musculoskeletal system</topic><topic>Myasthenia gravis</topic><topic>Neuromuscular junctions</topic><topic>Obesity</topic><topic>Oxidation</topic><topic>Oxidative stress</topic><topic>Physical fitness</topic><topic>Proteins</topic><topic>Review</topic><topic>Sarcopenia</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liao, Tingfeng</creatorcontrib><creatorcontrib>Xiong, Lijiao</creatorcontrib><creatorcontrib>Wang, Xiaohao</creatorcontrib><creatorcontrib>Yang, Shu</creatorcontrib><creatorcontrib>Liang, Zhen</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Physical Education Index</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Diabetology and metabolic syndrome</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liao, Tingfeng</au><au>Xiong, Lijiao</au><au>Wang, Xiaohao</au><au>Yang, Shu</au><au>Liang, Zhen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mitochondrial disorders as a mechanism for the development of obese Sarcopenia</atitle><jtitle>Diabetology and metabolic syndrome</jtitle><date>2023-11-06</date><risdate>2023</risdate><volume>15</volume><issue>1</issue><spage>1</spage><epage>224</epage><pages>1-224</pages><artnum>224</artnum><issn>1758-5996</issn><eissn>1758-5996</eissn><abstract>Obese sarcopenia is a severe and prevalent disease in an aging society. Compared to sarcopenia alone, the development and advanced stage of obesity sarcopenia is faster and more severe. Diagnosis of the cause of adipocyte accumulation is also more complicated; however, no effective pharmacological treatment is available. Chronic inflammation is one of the causes of sarcopenia, and obese patients, who are more likely to develop chronic inflammation, may simultaneously suffer from obesity and sarcopenia. Mitochondrial metabolic disorders have been more easily observed in the tissue cells of patients with obesity and sarcopenia. Mitochondrial metabolic disorders include abnormal mtDNA release, mitochondrial autophagy, and dynamic mitochondrial disorders. Therefore, this review will reveal the mechanism of development of obesity myasthenia gravis from the perspective of mitochondria and discuss the currently existing small-molecule drugs.</abstract><cop>London</cop><pub>BioMed Central Ltd</pub><pmid>37926816</pmid><doi>10.1186/s13098-023-01192-w</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1758-5996
ispartof Diabetology and metabolic syndrome, 2023-11, Vol.15 (1), p.1-224, Article 224
issn 1758-5996
1758-5996
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_cd563a25562a47e185b7f5b9f818bfc6
source Publicly Available Content Database; PubMed Central
subjects Adipocytes
Atrophy
Autophagy
Body fat
Developmental stages
Diabetes
Diet
Disease
Disease susceptibility
Drug therapy
Exercise
Inflammation
Insulin resistance
Lipids
Metabolic disorders
Mitochondria
Mitochondrial DNA
Musculoskeletal system
Myasthenia gravis
Neuromuscular junctions
Obesity
Oxidation
Oxidative stress
Physical fitness
Proteins
Review
Sarcopenia
Type 2 diabetes
title Mitochondrial disorders as a mechanism for the development of obese Sarcopenia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T07%3A47%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mitochondrial%20disorders%20as%20a%20mechanism%20for%20the%20development%20of%20obese%20Sarcopenia&rft.jtitle=Diabetology%20and%20metabolic%20syndrome&rft.au=Liao,%20Tingfeng&rft.date=2023-11-06&rft.volume=15&rft.issue=1&rft.spage=1&rft.epage=224&rft.pages=1-224&rft.artnum=224&rft.issn=1758-5996&rft.eissn=1758-5996&rft_id=info:doi/10.1186/s13098-023-01192-w&rft_dat=%3Cgale_doaj_%3EA771651301%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c523t-23fa5e20766913fbbc15cf8f43c2843fcfcfc256b7a3651bce417a78ba3435b13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2890075962&rft_id=info:pmid/37926816&rft_galeid=A771651301&rfr_iscdi=true